Want to see IN:SANOFI full AI Analyst Report?
SANOFI Stock Chart & Stats
₹4142.75
₹54.40(0.91%)
At close: 4:00 PM EST
₹4142.75
₹54.40(0.91%)
Day’s Range― - ―
52-Week Range₹3,057.60 - ₹6,368.80
Previous CloseN/A
Volume15.46K
Average Volume (3M)3.77K
Market Cap
₹79.58B
Enterprise Value₹73.53B
Total Cash (Recent Filing)₹2.75B
Total Debt (Recent Filing)₹178.00M
Price to Earnings (P/E)25.7
Beta0.75
Next Earnings
Jul 28, 2026EPS Estimate
44.4Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)98.01
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)168.05
Revenue Forecast (FY)₹19.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very low leverage profile provides durable financial flexibility, allowing the company to fund capex, sustain dividends, or pursue strategic M&A without needing external debt. Over 2–6 months this resilience reduces refinancing and solvency risk and supports steady capital allocation.
Strong Cash GenerationFCF that closely tracks net income and a large 2025 FCF increase indicate high earnings quality and reliable internal funding. This supports reinvestment, shareholder returns and less reliance on external financing, strengthening sustainability of operations over the medium term.
High Operating ProfitabilityConsistently high EBIT and healthy net margins reflect structural pricing power and efficient cost structure in core therapies. Durable margin levels support cash flows and ROIC, enabling continued R&D and commercial investment even if top-line growth moderates.
Bears Say
Revenue Decline & Choppy GrowthA weakening top-line trend erodes the revenue base that funds R&D, salesforce and brand investment. Persistent or renewed declines could force margin trade-offs, reduce scale benefits, and limit the company's ability to finance growth initiatives through internal cash over the medium term.
Material Gross Margin CompressionA sharp reduction in gross margin materially lowers earnings power and free cash generation. If driven by structural pricing pressure or higher input costs, margin recovery may require product mix shifts or cost restructuring, reducing long-term operational leverage and cash flow resilience.
Volatile Operating Cash FlowVolatile OCF and intermittent weak coverage signal working-capital swings that can make cash availability unpredictable. Even with low debt, inconsistent cash conversion complicates planning for capex, dividends or inventory financing and elevates operational risk over coming quarters.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3057.60 and its highest was ₹6368.80 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹79.58B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Jul 28, 2026 which is in 26 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Apr 28, 2026. The company reported ₹44.5 earnings per share for the quarter, missing the consensus estimate of ₹44.6 by -₹0.1.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹48 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate is 44.4.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹44.5 in its last earnings report, missing expectations of ₹44.6. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―